Thymosin Alpha-1 vs AOD-9604 Side-Effect Profile Head-to-Head
HealthRX.com
Thymosin alpha-1 has more trial safety data than AOD-9604
Key numbers
- 1,349 adultsAdults in 10 randomized hepatitis B trials of thymosin alpha-1, pooled in a 2026 Cochrane reviewSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- 1,056 peoplePeople in the 5 trials of thymosin alpha-1 that fed the serious adverse event estimate, per the Cochrane reviewSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- 4,400 peoplePeople enrolled in Zadaxin trials, per manufacturer-linked authors, who describe adverse experiences as infrequent and mildSource: fda.gov, as cited Nov 7, 2026
- 1.6 mgItalian Zadaxin label dose of thymosin alpha-1 for vaccine adjuvant use, given twice weeklySource: fda.gov, as cited Nov 7, 2026
At a glance
- FDA status / Neither is approved in the US [2][4]
- Thymosin alpha-1 safety data / 10 randomized hepatitis B trials, 1,349 adults, pooled in a 2026 Cochrane review [1]
- AOD-9604 safety data / Limited in humans; FDA reports serious adverse events of unclear cause, without detail [3][4]
- Shared regulatory flag / Both sit in FDA's 'nominated but withdrawn' table with immunogenicity concerns posted [3]
- Where thymosin alpha-1 is approved / Italy (vaccine adjuvant), India (chronic hepatitis B), Hong Kong, per FDA [2]
What can be compared, and what cannot
The two peptides are different molecules. Thymosin alpha-1 is a 28-amino-acid peptide originally isolated from thymosin fraction 5, a thymus extract; the synthetic version is called thymalfasin, and the finished injection sold outside the US is branded Zadaxin at 1.6 mg per vial [2]. It is described as an immune modulator that augments T-cell function [6]. AOD-9604 is a 16-amino-acid fragment of human growth hormone: hGH amino acids 177 to 191 with an extra tyrosine at the N-terminus, which is why it is also called hGH fragment 176-191 [7].
For thymosin alpha-1 there are randomized trials that counted adverse events. For AOD-9604 there is no approved label, and the main safety statements come from regulators.
Thymosin Alpha-1: What the Trials Report
The largest single source of comparative safety numbers is a 2026 Cochrane review of thymosin alpha-1 in chronic hepatitis B: 10 randomized trials, 1,349 adults, published between 1991 and 2018 and run in Bangladesh, China, Italy, Korea, Singapore and Taiwan [1]. Thymosin alpha-1, alone or added to interferon, lamivudine, entecavir or tenofovir, was compared with placebo, no treatment or the same co-treatment. The reviewers found it may have caused fewer serious adverse events than the comparison treatments (risk ratio 0.72, 95% CI 0.53 to 0.99; 5 trials, 1,056 people; low-certainty evidence) and fewer non-serious adverse events (risk ratio 0.47, 95% CI 0.27 to 0.83; very low-certainty evidence) [1]. The same review rated its effect on the disease itself as uncertain, with reviewers saying they were not sure it helps [1].
Two other data points matter for side effects. FDA's search of its adverse-event database on April 22, 2024 found zero reports for thymosin alpha-1 [2]. That shows only that FDA found no reports in the database it searched; it does not establish that the peptide has no side effects. Separately, authors tied to the manufacturer report more than 4,400 people enrolled in trials and more than 17 million doses of Zadaxin given after marketing, with adverse experiences described as infrequent and mild [2]. That is company-linked data rather than an independent audit.
Smaller trials add little on the safety side. A 1991 placebo-controlled pilot in 12 people with chronic hepatitis B reported no significant side effects in either the thymosin or placebo group [8]. In the 361-patient ETASS sepsis trial, the investigators recorded no serious drug-related adverse event [9].
The Italian Zadaxin label says the product is not for children, is contraindicated in pregnancy and breastfeeding, and calls for caution in people with allergies or autoimmune disease and with other immune-modulating drugs [2]. Its regimen is 1.6 mg subcutaneously or intramuscularly twice weekly for 4 weeks starting at the first vaccination, repeated from week 8 to week 12 at the second vaccination [2]. There is no US-approved dose [2].
AOD-9604: What Is Documented
AOD-9604 has no approved label and no approved dose. A 2026 review concludes that human evidence is limited and largely short-term, and notes that the sponsor's safety summary was published in a small journal in 2013 [4]. FDA has posted more directly. AOD-9604 sits in the agency's 'nominated but withdrawn' table, and the concerns FDA lists include a significant immunogenicity risk for certain routes of administration from peptide impurities and characterization problems, 'no, or only limited, safety information', and the statement that FDA 'has also identified serious adverse events that may be associated with AOD-9604, though causality is not clear' [3]. Removal from category 2 was not a finding that it is safe [3].
The main human obesity trial tested an oral drug candidate for 24 weeks (534 enrolled, 502 randomized) and failed to show a significant benefit on the primary weight-loss endpoint [4]. The 2026 review notes this rests on sponsor-reported phase 2 results rather than peer-reviewed randomized trials [4]. A separate 2026 review of gray-market peptides notes that rigorous human safety data are scarce and there is potential for serious harm [10].
Animal data are the basis for most claims. In obese Zucker rats, oral AOD9604 at 500 microgram/kg per day for 19 days did not worsen insulin sensitivity on euglycemic clamp, unlike intact growth hormone [11]. That is a rat finding and does not establish human safety.
Side by Side
| What is known | Thymosin alpha-1 | AOD-9604 |
|---|---|---|
| FDA approval | None; four US orphan drug designations as of December 2024, which are not approvals [2] | None [4] |
| Human safety record | 10 randomized hepatitis B trials, 1,349 adults, pooled in 2026 [1] | Limited [4] |
| Regulator statement on safety | FDA lists a significant immunogenicity risk for certain routes of administration [3]; an April 2024 adverse-event database search found zero reports [2] | FDA identified serious adverse events that may be associated, causality unclear, no details [3] |
| Named contraindications | Italian Zadaxin label: contraindicated in pregnancy and breastfeeding; not for children; caution with allergies or autoimmune disease [2] | No approved label; see FDA's compounding safety concerns [3] |
| How FDA treats it for compounding | 'Nominated but withdrawn' table; outsourcing-facility list category 3, nominated without adequate support [3][14] | 'Nominated but withdrawn' table; in no category on the pharmacy or outsourcing-facility lists [3][15][14] |
Questions worth asking
What the Regulators Say About Both
Neither peptide is FDA-approved [2][4], and compounded drugs are not FDA-approved either: FDA does not review their safety, effectiveness or quality before marketing [16]. Both appear in the agency's 'nominated but withdrawn' table, and the immunogenicity concerns FDA posted for each remain on its page [3].
For thymosin alpha-1, FDA's Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on both the free base and the acetate on December 4, 2024; members who voted no cited no compelling evidence of clinical effectiveness and safety [17]. Outside the US, FDA lists national authorizations in Italy for use as an adjuvant to influenza vaccination in immunocompromised people, in India for chronic hepatitis B, and in Hong Kong [2].
AOD-9604 appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians or on its list for outsourcing facilities [15][14]. Neither peptide is among the six in HHS's October 2026 draft enforcement-discretion policy for compounded peptides [20].
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
Frequently asked questions
Which of these two peptides has more safety data?
Does AOD-9604 cause serious side effects?
Does AOD-9604 raise IGF-1?
Does thymosin alpha-1 cause autoimmune disease?
Are either of these FDA-approved?
What does the thymosin alpha-1 label warn about?
References
Show all 21 referencesHide references
- Naing C, Ni H, Aung HH, Aye SN, Nikolova D, Poovorawan Y, et al. Thymosin-ɑ1 for people with chronic hepatitis B. Cochrane Database Syst Rev. 2026;9(9):CD014610.
- U.S. Food and Drug Administration.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, RuchaŁa M. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne). 2026;17:1822475.
- World Anti-Doping Agency.
- Ancell CD, Phipps J, Young L. Thymosin alpha-1. Am J Health Syst Pharm. 2001;58(10):879-85; quiz 886-8.
- Cox HD, Smeal SJ, Hughes CM, Cox JE, Eichner D. Detection and in vitro metabolism of AOD9604. Drug Test Anal. 2015;7(1):31-8.
- Mutchnick MG, Appelman HD, Chung HT, Aragona E, Gupta TP, Cummings GD, et al. Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial. Hepatology. 1991;14(3):409-15.
- Wu J, Zhou L, Liu J, Ma G, Kou Q, He Z, et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit Care. 2013;17(1):R8.
- Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026;56(8):1921-1935.
- Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-8.
- Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-9.
- GRAS Notices.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Official web page.
- U.S. Food and Drug Administration.
- Goldstein AL, Goldstein AL. From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opin Biol Ther. 2009;9(5):593-608.
- Tuthill C. Issues in pharmaceutical development of thymosin alpha1 from preclinical studies through marketing. Ann N Y Acad Sci. 2007;1112:351-6.
- Official web page.
- World Anti-Doping Agency.